The National Organization for Rare Disorders (NORD) has awarded Shire the 2010 Partners in Progress Corporate Award for its efforts in developing a treatment for Type 1 Gaucher disease.
The award was given to recognise Shire’s development of VPRIV(TM), a human cell line derived enzyme replacement therapy (ERT), and for providing the therapy to patients ahead of commercial approval through early access programmes.
In 2007, the company received a Corporate Leadership Award for the development of an ERT for Hunter syndrome.
Each year, NORD honours organisations that have made a positive contribution to furthering the needs of the patient community.
VPRIV was approved by the Food and Drug Administration (FDA) on 26 February 2010 and has also been granted accelerated assessment by the European Medicines Agency (EMA) in the EU.
